Andreas Norlin

Directeur Technique/Scientifique/R&D chez ASCELIA PHARMA AB

Fortune : 12 367 $ au 31/05/2024

54 ans

Health Technology

Consumer Services

Technology Services

Postes actifs de Andreas Norlin

Sociétés	Poste	Début	Fin
ASCELIA PHARMA AB	Directeur Technique/Scientifique/R&D	01/01/2020	-
ApoGlyx AB ApoGlyx AB BiotechnologyHealth Technology ApoGlyx AB engages in research and development of aquaporin inhibitors. It conducts sales of know-how, licenses, and chemical substance in biochemistry. The company was founded by Per Ola Kjellbom on April 22, 2008 and is headquartered in Lund, Sweden.	Directeur/Membre du Conseil	-	-
Desupervised ApS Desupervised ApS Information Technology ServicesTechnology Services Part of Hamiltonian Holding ApS, Desupervised ApS is a Danish company that provides artificial intelligence software services. The company is based in Copenhagen, Denmark.	Directeur/Membre du Conseil	-	-

Sociétés	Poste	Début	Fin
Xkout Bioscience AB	Fondateur	-	-

University of Lund

Doctorate Degree

Internationale

Suède	5
Danemark	2

Opérationnelle

Sectorielle

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	1
ASCELIA PHARMA AB	Health Technology

Entreprise privées	3
ApoGlyx AB ApoGlyx AB BiotechnologyHealth Technology ApoGlyx AB engages in research and development of aquaporin inhibitors. It conducts sales of know-how, licenses, and chemical substance in biochemistry. The company was founded by Per Ola Kjellbom on April 22, 2008 and is headquartered in Lund, Sweden.	Health Technology
Xkout Bioscience AB
Desupervised ApS Desupervised ApS Information Technology ServicesTechnology Services Part of Hamiltonian Holding ApS, Desupervised ApS is a Danish company that provides artificial intelligence software services. The company is based in Copenhagen, Denmark.	Technology Services